37 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
17 Dec 20
Current report (foreign)
6:01am
to be carbon neutral across our value chain in FY2020 and help achieve our goal of reaching zero carbon emissions from operations by 2040. To reflect our … the way we operate through increased innovation and efficiency. In 2020, Takeda announced that we would become carbon neutral and implement a long-term
6-K
TAK
Takeda Pharmaceutical Co
14 Jan 20
Current report (foreign)
6:56am
of 2x Net Debt / adjusted EBITDA within Fiscal Years Ending March 2022 – March 2024
Significant Commitment to and Investment in Carbon Neutrality … , financial outlook, and ongoing sustainability efforts, including its newly established commitment to carbon neutrality across its value chain.
“Last
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 Jun 21
Current report (foreign)
7:38am
become a carbon neutral business in FY2019, so now we have turned to our longer-term targets – a 40% reduction in greenhouse emissions from our … companies to achieve Global Top Employer certification for 2021, the fourth year in a row GLOBAL TOP EMPLOYER CERTIFIED CARBON NEUTRALITY: Takeda became
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:14am
and achieved carbon neutrality across our entire value chain for our scope 1 and 2 and currently estimated9 scope 3 greenhouse gas (GHG) emissions through … the purchase of renewable energy certificates and carbon offsets. We continue to reduce our operational carbon footprint and are now committed
6-K
TAK
Takeda Pharmaceutical Co
19 Jul 21
Current report (foreign)
6:02am
. Beginning with FY2019 greenhouse gas (GHG) emissions, the company achieved carbon neutrality (emission from the company operation (Scopes 1 and 2 … , and investment in renewable energy certificates and high-quality, verified carbon offsets. By 2040, the company commits to being carbon zero without
6-K
b9jcosw ua6
1 Feb 24
Current report (foreign)
6:18am
6-K
137fqmqa2ehn8
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
122g7w
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
6-K
to4sbejk k3f
27 May 20
Current report (foreign)
6:12am
6-K
y5305hf5
1 Nov 21
Current report (foreign)
6:04am
6-K
EX-99.1
f4t0o9gel1nbb37a
6 Jul 23
Current report (foreign)
6:18am
6-K
dxwvh1g2nvs4ert6hzwm
11 May 21
Current report (foreign)
6:08am
6-K
7tkkvcug
9 May 24
Current report (foreign)
6:01am
6-K
EX-99.1
o5omjejmknde5
30 Nov 23
Current report (foreign)
6:01am
6-K
EX-99.1
yvhbkjii5
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
y8n81oy3
28 May 21
Current report (foreign)
6:04am
6-K
EX-99.1
0a7hq28
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
emrsn0ce8eue1vigyin3
27 Oct 22
Current report (foreign)
6:01am
6-K
EX-99.1
etfi t9fbn
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
2zp47
1 Feb 24
Current report (foreign)
6:06am